US › Healthcare

Curis Inc (CRIS)

US · Healthcare · Biotechnology

$1.09-2.68%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-8.6M

EPS

$-4.02

EPS estimate

$-5.70

EPS came in at -4.02 against a street estimate of -5.70 — a beat of 29.5%.

Key statistics

Market cap

$2.7M

P/E

0.3

Forward P/E

0.0

P/B

0.59

Book value

$2.41

EPS (TTM)

$3.65

52-week high

$37.60

52-week low

$1.11

50-day MA

$3.34

200-day MA

$12.81

Beta

3.00

Analyst view

Analysts rate Curis Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $42.67.

Shareholding

Insiders

6.46%

Institutions

29.05%

Largest institutional holders

Fund	Stake
Bleichroeder LP	9.10%
Stonepine Capital Management Llc	8.91%
Nantahala Capital Management, LLC	4.78%
Sphera Funds Management Ltd.	4.77%
Cable Car Capital LLC	3.19%
Dauntless Investment Group, LLC	1.58%
Vanguard Capital Management, LLC	0.90%
Renaissance Technologies Corp	0.88%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Curis Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.